Drug Database
HE

Hep A-Vi (ViATIM / ViVAXIM)

✓ Approved

Sanofi S.A · 疫苗 · 疫苗

什么是 Hep A-Vi?

Hep A-Vi 是一种疫苗,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名ViATIM, ViVAXIM
公司Sanofi S.A
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

Hep A-Vi 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsTyphoid fever✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

相关研究文献

PubMedExpert review of pharmacoeconomics & outcomes research2026-11-18

Cost-effectiveness of Umeclidinium/Vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov Model.

Buendía Jefferson Antonio JA

To evaluate the lifetime cost-effectiveness of once-daily umeclidinium/vilanterol (UMEC/VI) versus twice-daily aclidinium monotherapy for symptomatic chronic obstructive pulmonary disease (COPD) in Colombia. A lifetime Markov model with monthly cycles simulated moderate-to-very-severe COPD in a cohort aged 65 years, incorporating age- and severity-specific background mortality and a 12% case-fatality probability after each severe exacerbation. Comparative efficacy came from a published network meta-analysis; comparator exacerbation probabilities were derived on the rate scale. Costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. Deterministic, scenario, and probabilistic sensitivity analyses were performed. UMEC/VI yielded 8.108 QALYs at US$24,956 per patient versus 6.312 QALYs and US$29,994 for aclidinium (incremental 1.796 QALYs; US$5,038 saved), making UMEC/VI dominant (net monetary benefit US$14,341). UMEC/VI was dominant in 94.7% and cost-effective in 98.6% of probabilistic simulations. Without its exacerbation benefit, UMEC/VI was not cost-effective (net monetary benefit -US$859). UMEC/VI is a high-value COPD maintenance therapy in Colombia, driven by exacerbation reduction rather than drug pricing and conditional on persistence of its clinical benefit.

PMID 43048953
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Color Evaluation of Tinted Sunscreens on Diverse Skin Tones.

Dumbuya Hawasatu H, Yamamoto Mariana Mitie MM, Munoz Laure L, Danoy Alix A et al.

Topical formulations incorporating visible light (VL)-attenuating pigments, specifically iron oxides (FeO) alongside broad-spectrum sunscreens, protect against VL-induced hyperpigmentation and aid in managing pigmentary disorders. However, the market suffers from limited shade ranges that often exclude individuals with darker skin tones; even self-proclaimed "universal" shades frequently leave an aesthetically unacceptable "ashy" or grayish cast. Since the cosmetic elegance of sunscreens is critical for patient compliance, this study aims to evaluate the color matching and acceptability of seven commercially available tinted sunscreens in a diverse cohort of FST III-VI individuals. The design consists of a single-center, double-blind, randomized, split-face study, including in a diverse cohort of FST III-VI individuals (n = 40). Color matching and acceptability of seven commercially available tinted sunscreens (tailored mineral, universal mineral, and hybrid formulations) were evaluated using both investigator and subject questionnaires, plus clinical imaging and analyses. During baseline swatch testing, participants with FST V-VI unanimously rejected the "universal" inorganic sunscreen. Furthermore, investigator and subject questionnaires, plus image analyses revealed that while tailored tinted formulations (inorganic or hybrid) achieved high-to-moderate satisfaction for FST III-IV phototypes, scores dropped notably for individuals with higher FST and deeper complexions. Our data show that skin evenness and blendability are just as vital to product adoption as preventing visible residue. Collectively, our findings demonstrate that optimizing FeO variants and UV filter configurations in sunscreen formulations is critical to achieving consumer satisfaction across diverse populations. We hope this research clarifies the key factors driving successful color matching and satisfaction in individuals with SOC, thereby optimizing sunscreen compliance and clinical outcomes for patients with darker skin tones.

PMID 43047227
阅读全文 →
PubMedRSC advances2026-11-18

Induction of breast cancer cell apoptosis by novel pyrrolo[2,3-d]pyrimidine analogs through modulation of the Bax/Bcl-2 ratio.

Khademi Ashkan A, Sayahi Mohammad Hosein MH, Irajie Cambyz C, Haghpanah Vahid V et al.

Breast cancer remains one of the most commonly diagnosed malignancies worldwide, and developing novel cytotoxic agents that overcome therapeutic resistance remains a major priority in anticancer drug discovery. Building on the pyrrolo[2,3-d]pyrimidine scaffold of tofacitinib, a series of fifteen tofacitinib-derived analogs (5a-n) with aryl substitutions was synthesized and evaluated for cytotoxic activity against Hep-G2, PC-3, and MCF-7 cancer cell lines. Structure-activity relationship (SAR) analysis revealed that para-substitution outperformed ortho-substitution, and among halogens, potency followed the order: Br > Cl > F. The para-bromo analog 5e emerged as the most potent compound against MCF-7 cells (IC50 = 0.99 ± 0.20 µM) and showed strong activity against PC-3 (10.70 ± 0.45 µM). Flow cytometric analysis showed that 5e induced a concentration-dependent response in MCF-7 cells, causing a significant G1 cell cycle arrest that effectively blocks the G1/S transition checkpoint. This block induced programmed cell death, resulting in pronounced late apoptosis (64.5% vs. 1.06% in the control) and a 9.4-fold increase in the Bax/Bcl-2 ratio. To explore a plausible mechanism of action for compound 5e, in silico docking and molecular dynamics simulations against the JAK1 ATP-binding pocket were also performed. Together, these results identify 5e as a promising anticancer lead and provide a validated structural template for linking the pyrrolo[2,3-d]pyrimidine scaffold to cytotoxic and pro-apoptotic activity. When combined with mechanistic and computational evidence, the clear SAR trends based on halogen type and position provide strong support for optimizing the next generation of anticancer agents, especially in the context of therapeutic resistance in breast cancer.

PMID 43048348
阅读全文 →
PubMedOxford medical case reports2026-11-18

Hepatic tuberculosis mimicking a complex cystic hepatic neoplasm with occult Miliary pulmonary involvement: a case report and narrative review.

Alkhanafsa Mohammed M, Ababneh Ra'ed R, Wafi Jamil J, Deek Soud S et al.

Hepatic tuberculosis is a rare extrapulmonary manifestation that may mimic hepatobiliary malignancy or complex cystic lesions, resulting in diagnostic challenges. A 36-year-old Filipino woman without recognized immunocompromising conditions presented with fever, weight loss, jaundice, and right upper quadrant pain. Imaging showed a multiloculated cystic lesion in hepatic segments V/VI with focal biliary prominence. Liver biopsy demonstrated necrotizing and non-necrotizing granulomatous inflammation with focally positive Ziehl-Neelsen staining. Tissue MTB-PCR detected Mycobacterium tuberculosis without rifampicin resistance, and culture confirmed M. tuberculosis complex susceptible to streptomycin, isoniazid, rifampicin, and ethambutol. CT chest showed diffuse bilateral micronodules in a miliary pattern; initial sputum smear and PCR were negative, but final sputum culture became positive at 6 weeks. Standard 2HRZE/4HR therapy was initiated, with clinical and biochemical improvement at 1 month. Hepatic tuberculosis should be considered in atypical cystic hepatic lesions, and tissue diagnosis is essential to avoid unnecessary invasive procedures.

PMID 43048224
阅读全文 →
PubMedPhysical chemistry chemical physics : PCCP2026-11-18

Resolving heterogeneous chromium redox kinetics in complex matrices via physics-informed XRF and vis-NIR spectrometry.

Wang Qingya Q, Wu Shuliang S, Tao Liangliang L, Zou Xiaoping X et al.

In situ characterization of chromium (Cr) redox kinetics in heterogeneous mine tailing is often limited by spectral overlaps and matrix-dependent signal interference. While machine learning provides a tool for spectral deconvolution, empirical models frequently yield results that are inconsistent with physical laws when applied to complex geochemical matrices. This study presents a physics-informed learning framework, KI-BLS-Net, which integrates X-ray fluorescence and vis-NIR spectroscopy with theoretical rate limits derived from density functional theory and mass-action laws. Using Cr(VI) reduction in mine tailing as a case study, the framework resolved transient redox speciation with a root-mean-square error of 0.14 mg L-1 by enforcing kinetic consistency during the training process. By defining a kinetic efficiency metric, we quantified the interfacial passivation resistance, demonstrating that secondary mineral shielding can suppress reaction rates by approximately two orders of magnitude despite favorable thermodynamic driving forces. Spectral saliency analysis identified a regime shift from iron-mediated reduction to surface-hydroxyl-controlled passivation, a mechanism corroborated by X-ray diffraction and scanning electron microscopy with energy-dispersive X-ray spectroscopy. The integration of atomic and molecular spectrometry with physics-informed modeling provides a robust method for the dynamic analysis of redox-controlled environmental systems.

PMID 43048870
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

SuFEx-Enabled Tyrosine Specific Bioconjugation of Near-Infrared Fluorophores.

McKay Paula T PT, Nashawati Stefan S, Kodisana Mohan M, Aden Jude E JE et al.

Sulfur (VI) fluoride exchange (SuFEx) chemistry has been widely applied in small-molecule medicinal chemistry, but its translation to near-infrared (NIR) fluorophores and application to antibody labeling remain largely unexplored. Here, we report a general synthetic approach for the preparation of aryl sulfonyl fluoride-functionalized indolenines and their incorporation into heptamethine cyanine (Cy7) fluorophores. The strategy is compatible with a broad range of indolenine substrates bearing diverse electronic and solubilizing substituents, enabling the synthesis of a library of water-soluble, SuFEx-enabled Cy7 fluorophores. Using SAT-NIR-746-SF as a lead probe, we demonstrate that the aryl sulfonyl fluoride handle is stable under physiologically relevant conditions (t1/2 > 18 h at pH 7.4) and enables efficient antibody labeling (degree of labeling up to 6.1) under mild aqueous conditions. The degree of labeling can be systematically controlled by varying reaction pH, incubation time, and reagent stoichiometry. The strategy was successfully applied to therapeutic monoclonal antibodies, including trastuzumab, panitumumab, and cetuximab, and the resulting conjugates were stable under acidic, physiological, and serum conditions. Amino acid selectivity assays and tandem mass spectrometry-based proteomics of labeled trastuzumab confirmed modification exclusively at tyrosine residues, establishing the tyrosine-selective nature of this conjugation platform. SAT-NIR-746-SF-conjugated secondary antibodies provided specific labeling of phospho-histone H3 (H3S10P) in confocal immunofluorescence microscopy. These results establish SuFEx-enabled Cy7 fluorophores as a practical platform for tyrosine-selective antibody bioconjugation and demonstrate their utility in fluorescence imaging applications.

PMID 43046850
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Hep A-Vi